Legal battles
over gene patents and uncooperative patent holders threaten the widespread implementation of personalized medicine.
An ongoing legal battle
over gene patents has led many scientists to ask whether such claims help or hinder research...
Craig Venter, the molecular biologist whose DNA sequences are the focus of an international row
over gene patenting, is leaving the US National Institutes of Health.
Not exact matches
It has used broad
gene patents to operate a monopoly
over testing for the two BRCA
genes, which when mutated can cause inherited forms of breast cancer.
Prasher and Chalfie were awarded a
patent for the use of GFP as a marker of
gene expression; in total, it earned Prasher just a few hundred thousand dollars in royalties
over 15 years.
Myriad Genetics owns the
patent over certain breast cancer
genes, effectively giving them ownership
over any test involving the
genes.
So why the fuss
over patenting a fragment whose use lies only in identifying full - length
genes?
Myriad Genetics has used broad
gene patents to operate a monopoly
over testing for the two BRCA
genes, which when mutated can cause inherited forms of breast cancer.